HomeCompareHGYMF vs JNJ

HGYMF vs JNJ: Dividend Comparison 2026

HGYMF yields 1.84% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HGYMF wins by $806.00 in total portfolio value
10 years
HGYMF
HGYMF
● Live price
1.84%
Share price
$34.99
Annual div
$0.64
5Y div CAGR
24.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.1K
Annual income
$2,438.21
Full HGYMF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HGYMF vs JNJ

📍 HGYMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHGYMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HGYMF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HGYMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HGYMF
Annual income on $10K today (after 15% tax)
$156.55/yr
After 10yr DRIP, annual income (after tax)
$2,072.48/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $1,913.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HGYMF + JNJ for your $10,000?

HGYMF: 50%JNJ: 50%
100% JNJ50/50100% HGYMF
Portfolio after 10yr
$30.7K
Annual income
$3,563.81/yr
Blended yield
11.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HGYMF
No analyst data
Altman Z
5.3
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HGYMF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHGYMFJNJ
Forward yield1.84%2.13%
Annual dividend / share$0.64$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24.7%28%
Portfolio after 10y$31.1K$30.3K
Annual income after 10y$2,438.21$4,689.40
Total dividends collected$9.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HGYMF vs JNJ ($10,000, DRIP)

YearHGYMF PortfolioHGYMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,930$229.67$10,592$272.30+$338.00HGYMF
2$11,987$292.55$11,289$357.73+$698.00HGYMF
3$13,200$373.93$12,123$472.89+$1.1KHGYMF
4$14,604$479.89$13,141$629.86+$1.5KHGYMF
5$16,245$618.75$14,408$846.81+$1.8KHGYMF
6$18,185$802.13$16,021$1,151.60+$2.2KHGYMF
7$20,504$1,046.42$18,122$1,588.22+$2.4KHGYMF
8$23,314$1,375.06$20,930$2,228.20+$2.4KHGYMF
9$26,768$1,822.17$24,792$3,191.91+$2.0KHGYMF
10$31,080$2,438.21$30,274$4,689.40+$806.00HGYMF

HGYMF vs JNJ: Complete Analysis 2026

HGYMFStock

Hogy Medical Co.,Ltd., together with its subsidiaries, provides medical-use and non-woven fabric, surgical kit, and other products in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, personal protective equipment and wearables, drapes, packaged products, instrument table covers, and wraps; and Tigalyer, a non-woven fabric with liquid barrier properties for waterproofing applications. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stands; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers Opera Master, a surgery management system; ME equipment operation management system; narcotics/poisons box, an automatic drug reading management system using radio frequency identification; endoscope holders; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was incorporated in 1961 and is headquartered in Tokyo, Japan.

Full HGYMF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HGYMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HGYMF vs SCHDHGYMF vs JEPIHGYMF vs OHGYMF vs KOHGYMF vs MAINHGYMF vs ABBVHGYMF vs MRKHGYMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.